These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 31827703)

  • 1. Tetramethylpyrazine Analogue T-006 Exerts Neuroprotective Effects against 6-Hydroxydopamine-Induced Parkinson's Disease
    Zhou H; Shao M; Yang X; Li C; Cui G; Gao C; Di L; Zhong H; Wang Y; Zhang Z; Lee SM
    Oxid Med Cell Longev; 2019; 2019():8169125. PubMed ID: 31827703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxyphylla A exerts antiparkinsonian effects by ameliorating 6-OHDA-induced mitochondrial dysfunction and dyskinesia in vitro and in vivo.
    Shao M; Zhao C; Pan Z; Yang X; Gao C; Kam GH; Zhou H; Lee SM
    Chem Biol Interact; 2024 Nov; 403():111224. PubMed ID: 39233265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotective and neurogenic effects of novel tetramethylpyrazine derivative T-006 in Parkinson's disease models through activating the MEF2-PGC1α and BDNF/CREB pathways.
    Chen H; Cao J; Zha L; Wang P; Liu Z; Guo B; Zhang G; Sun Y; Zhang Z; Wang Y
    Aging (Albany NY); 2020 Jul; 12(14):14897-14917. PubMed ID: 32710729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetramethylpyrazine Analogue CXC195 Protects Against Dopaminergic Neuronal Apoptosis via Activation of PI3K/Akt/GSK3β Signaling Pathway in 6-OHDA-Induced Parkinson's Disease Mice.
    Chen L; Cheng L; Wei X; Yuan Z; Wu Y; Wang S; Ren Z; Liu X; Liu H
    Neurochem Res; 2017 Apr; 42(4):1141-1150. PubMed ID: 28005221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic effects of multifunctional tetramethylpyrazine nitrone on models of Parkinson's disease in vitro and in vivo.
    Guo B; Xu D; Duan H; Du J; Zhang Z; Lee SM; Wang Y
    Biol Pharm Bull; 2014; 37(2):274-85. PubMed ID: 24305623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons.
    Yuan WJ; Yasuhara T; Shingo T; Muraoka K; Agari T; Kameda M; Uozumi T; Tajiri N; Morimoto T; Jing M; Baba T; Wang F; Leung H; Matsui T; Miyoshi Y; Date I
    BMC Neurosci; 2008 Aug; 9():75. PubMed ID: 18671880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice.
    Burgaz S; García C; Gómez-Cañas M; Navarrete C; García-Martín A; Rolland A; Del Río C; Casarejos MJ; Muñoz E; Gonzalo-Consuegra C; Muñoz E; Fernández-Ruiz J
    Mol Cell Neurosci; 2021 Jan; 110():103583. PubMed ID: 33338634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A potential target for the treatment of Parkinson's disease: effect of lateral habenula lesions.
    Han B; Jin HJ; Song MY; Wang T; Zhao H
    Parkinsonism Relat Disord; 2014 Nov; 20(11):1191-5. PubMed ID: 25219971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ALCAR Exerts Neuroprotective and Pro-Neurogenic Effects by Inhibition of Glial Activation and Oxidative Stress via Activation of the Wnt/β-Catenin Signaling in Parkinsonian Rats.
    Singh S; Mishra A; Shukla S
    Mol Neurobiol; 2016 Sep; 53(7):4286-301. PubMed ID: 26223802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotection by neuropeptide Y in cell and animal models of Parkinson's disease.
    Decressac M; Pain S; Chabeauti PY; Frangeul L; Thiriet N; Herzog H; Vergote J; Chalon S; Jaber M; Gaillard A
    Neurobiol Aging; 2012 Sep; 33(9):2125-37. PubMed ID: 21816512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tetramethylpyrazine nitrone exerts neuroprotection via activation of PGC-1α/Nrf2 pathway in Parkinson's disease models.
    Guo B; Zheng C; Cao J; Luo F; Li H; Hu S; Mingyuan Lee S; Yang X; Zhang G; Zhang Z; Sun Y; Wang Y
    J Adv Res; 2024 Oct; 64():195-211. PubMed ID: 37989471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The anti-aging protein klotho alleviates injury of nigrostriatal dopaminergic pathway in 6-hydroxydopamine rat model of Parkinson's disease: Involvement of PKA/CaMKII/CREB signaling.
    Baluchnejadmojarad T; Eftekhari SM; Jamali-Raeufy N; Haghani S; Zeinali H; Roghani M
    Exp Gerontol; 2017 Dec; 100():70-76. PubMed ID: 29107062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. J24335 exerts neuroprotective effects against 6-hydroxydopamine-induced lesions in PC12 cells and mice.
    Pan Z; Shao M; Zhao C; Yang X; Li H; Cui G; Liang X; Yu CW; Ye Q; Gao C; Di L; Chern JW; Zhou H; Lee SM
    Eur J Pharm Sci; 2024 Mar; 194():106696. PubMed ID: 38199443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotective Effects of Tanshinone I Against 6-OHDA-Induced Oxidative Stress in Cellular and Mouse Model of Parkinson's Disease Through Upregulating Nrf2.
    Jing X; Wei X; Ren M; Wang L; Zhang X; Lou H
    Neurochem Res; 2016 Apr; 41(4):779-86. PubMed ID: 26537816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the antiparkinsonism and neuroprotective effects of hydrogen sulfide in acute 6-hydroxydopamine-induced animal model of Parkinson's disease: behavioral, histological and biochemical studies.
    Sarukhani M; Haghdoost-Yazdi H; Sarbazi Golezari A; Babayan-Tazehkand A; Dargahi T; Rastgoo N
    Neurol Res; 2018 Jul; 40(7):523-531. PubMed ID: 29726751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanisms underlying protective effects of quercetin against mitochondrial dysfunction and progressive dopaminergic neurodegeneration in cell culture and MitoPark transgenic mouse models of Parkinson's Disease.
    Ay M; Luo J; Langley M; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
    J Neurochem; 2017 Jun; 141(5):766-782. PubMed ID: 28376279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurorescue effects of VEGF on a rat model of Parkinson's disease.
    Yasuhara T; Shingo T; Muraoka K; Kameda M; Agari T; Wen Ji Y; Hayase H; Hamada H; Borlongan CV; Date I
    Brain Res; 2005 Aug; 1053(1-2):10-8. PubMed ID: 16045899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine D1 receptor agonism induces dynamin related protein-1 inhibition to improve mitochondrial biogenesis and dopaminergic neurogenesis in rat model of Parkinson's disease.
    Mishra A; Singh S; Tiwari V; Bano S; Shukla S
    Behav Brain Res; 2020 Jan; 378():112304. PubMed ID: 31626851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotective and behavioural assessments of an imidazolium compound (DBZIM) in a rat model of Parkinson's disease induced by 6-OHDA.
    Chan HH; Kumar S; Zhuo L
    Eur J Pharmacol; 2013 Sep; 715(1-3):405-13. PubMed ID: 23652161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activin A protects midbrain neurons in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Stayte S; Rentsch P; Li KM; Vissel B
    PLoS One; 2015; 10(4):e0124325. PubMed ID: 25902062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.